Direct Rx is recalling 24 bottles of Alprazolam C-IV (1 mg and 2 mg) tablets because of potential cross-contamination that occurred at the contract manufacturing facility, Ultra Tab Laboratories Inc. Alprazolam is a prescription medication used to treat anxiety and panic disorders. The recall involves approximately 16 bottles of the 1 mg strength and 8 bottles of the 2 mg strength distributed in Florida, Louisiana, and Georgia. No incidents or injuries have been reported to date.
Cross-contamination in pharmaceutical manufacturing can introduce unintended active ingredients into a medication, which may lead to unexpected side effects or dangerous interactions with other drugs. Because this is a controlled substance, the presence of foreign contaminants could pose moderate health risks to consumers.
You have 2 options:
Recall #: D-0650-2022; Dist. By: Par Pharmaceutical; Packaged and Distributed By: Direct Rx
Recall #: D-0651-2022; Dist. By: Par Pharmaceutical; Packaged and Distributed By: Direct Rx
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.